Description
Filgotinib is a potent and selective JAK1 inhibitor exhibiting 30-fold selectivity over JAK2. It was shown to inhibit Th1 and Th2 differentiation and to a lesser extent the differentiation of Th17 cells in vitro. Filgotinib has the potential for the treatment of rheumatoid arthritis and possibly other immune-inflammatory diseases